UroLift may offer improved early recovery period vs Rezūm for BPH
April 4th 2025“The differences in patient experience between UroLift System and Rezūm, particularly in terms of early recovery, sexual function, and overall satisfaction, are key considerations for both clinicians and patients selecting a treatment path," says Mark Rochester, MD, FRCS.
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
April 3rd 2025"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall survival is about 45 to 47 months," says Neeraj Agarwal, MD, FACS.
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
April 1st 2025“If it is as efficacious as it looks, we will have more patients who are getting effective standard of care treatment, not needing to go on to further treatment, not having recurrences, [having decreased] morbidity from repeated resections, and saving bladders in the process," says Eugene B. Cone, MD.
Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC
March 26th 2025"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC
March 25th 2025"Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.